Coronavirus

A Look at the Most Promising Candidates for a Covid-19 Vaccine

From the U.S. to Germany, scientists are working around the clock to find a vaccine against the novel coronavirus. While experts caution that the process will take time—and that it’s not even a sure bet one can be found—some researchers say a vaccine could be ready for emergency use by the end of the year. The Trump administration has announced “Operation Warp Speed” to have an inoculation ready as soon as possible.

Most of the programs are in their early stages, meaning the gold standard of data, clinical trials with “blinded” placebo and therapeutic groups, is still a ways off. In normal times, the process to approve a drug or vaccine is slow and painstaking. It can be accelerated but at the risk of incurring unforeseen harm. When rules are loosened in the desire to get a vaccine to market quickly, it’s important to cast a skeptical eye on too-good-to-be-true data. It’s also possible that more than one usable vaccine could emerge. In the polio epidemic of the 1950s, scientists developed two different kinds, first an injection and later oral drops, to help eradicate the disease.

Johnson & Johnson
Working on a $1 billion- plus effort with the U.S. government to test a vaccine, J&J plans to start human trials by September.

Inovio
Inovio kicked off its vaccine trial in April; the company is targeting larger studies this summer.

Moderna
The U.S. government has awarded the company almost $500 million in funding to develop and test its candidate. A patient trial is under way; early results could be available in late May or June.

Sinovac
The company says its inoculation can neutralize different strains of the virus.

Sanofi and GlaxoSmithKline
Sanofi is testing technology that’s already used in a flu shot, with Glaxo providing some of the ingredients. Patient trials could start in the second half of this year.

Imperial College London
Researchers have received funding for their vaccine project and aim to begin clinical trials in June.

Oxford University and AstraZeneca
AstraZeneca has agreed to make an experimental inoculation developed by researchers at Oxford. Already being studied in humans, it could reach late-stage trials by the middle of the year.

BioNTech and Pfizer
The German and American duo launched clinical trials of its vaccine in the U.S. and Europe. If it’s successful and approved by regulators, the drugmaker could start distributing the shot on an emergency-use basis in the fall.


If You Enjoy Articles Like This - Subscribe to the AMAC Daily Newsletter
and Download the AMAC News App

Sign Up Today Download

If You Enjoy Articles Like This - Subscribe to the AMAC Daily Newsletter!


Subscribe
Notify of
7 Comments
Newest
Oldest Most Voted
Inline Feedbacks
View all comments
anna hubert
2 years ago

The head of WHO said the poorest and the most needy are desperate for it we all know they are also most populated is that the plan? To depopulate Bill Gates makes no secret of it and his hand is in many a cookie jar in the vaccine development probably too.

Brian
2 years ago

If many doctors have already successfully treated CV patients with hydroxychloroquine coupled with azithromycin and zinc, why is big pharma being given billions to develop a vaccine that may or may not work any better than the flu shot? And why is Fauci pushing remdesivir which has no statistical benefit?

S T
2 years ago
Reply to  Brian

Bill Gates

anna hubert
2 years ago
Reply to  Brian

because he wants a vaccine,unfortunately Jonas Salk is dead

Linda Plante
2 years ago

Disappointing our government is funding this big pharma endeavor and really sad that President Trump wants it on a fast track. ?

Dave S
2 years ago
Reply to  Linda Plante

So, we should just stay in quarantine for a couple of years and hope? We should be doing everything we can to find a vaccine and end the suffering of hundreds of thousands, and potentially save the lives of as many. I’m glad the President is trying to find ways to safely accelerate the ponderous government approval process, and I don’t care if my tax dollars pay for it. I think most of the people in this country, anyone who cares about the lives of others wants a vaccine on a fast track. Now we need the Chinese government to suffer for this as much as we all have – they’re our enemy, not the President.

Marti Siegfried
2 years ago
Reply to  Dave S

Dave, I respect your opinion although I disagree with it. I do not think we should stay in quarantine for much longer even without a vaccine. Vaccines often take years to develop to be safe AND effective. And, like we know with the (yes, it is true according to many Drs.) comparable seasonal flu, vaccines are often not even 50% effective. Treatments, on the other hand, are safer and more effective. And, if a person has serious health problems, they can self-isolate until (what is now thought by many Drs. to be the seasonality of covid-19 like the seasonal flu should be occuring) this newer strain of cold/flu virus season passes. The fatality rate of covid 19 is incredibly low. One has a survival rate of 99.97% (as more testing has shown of cases vs deaths from covid only) IF they even get it in the first place. To me, treatments provide the answer since many Drs. say this virus has a similar makeup to the common cold, HIV, and Ebola–no vaccines have been found for them. I think much of the “we MUST have a vaccine before we can live free” versus “focus on treatments is because the media hype around this whole covid situation. It is turning out to be a comparatively mild virus in relation, some places, to seasonal flu, H1N1, MERS, and many other bugs that we have endured. I think, politically, though, the President has to take a leadership role in “trying to find a vaccine because the public is so scared and this IS an election year, a critical one at that. I agree too, that the Communist Chinese Party/CCP must face consequences. But I think a vaccine developed on a fast track, if even one can be found, could be unsafe and ineffective. My two cents….

7
0
Would love your thoughts, please comment.x
()
x